Overview
Location
United States, California, San Diego
Employees
51-200
Total raised
$1.3M
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 18
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 14, 2014 | Main reason startups get rejected by venture capital: “Crappy teams” | If a startup hasn’t thought through the clinical aspects, or doesn’t think through the competition or regulatory landscape. A lot of startups just haven’t really examined what a project should look like – and generally don’t have insight in... |
| Sep 17, 2014 | J&J launches Neuroscience Catalyst to seed academic spinouts | Janssen is helping operationalize the academic spinouts, as well as raise downstream venture financing, and design a clear exit strategy. Much like many of these pharma-academia partnerships, J&J will also provide in-kind support, allow... |
| Aug 25, 2014 | Startup’s antiviral drug combats HPV, new study shows | Hera Therapeutics doesn’t yet know the exact steps the antiviral takes, but it essentially blocks the pathway that allows the virus to make its DNA using cellular enzymes, Hostetler said. “It’s a nucleoside analog, and that’s all we’re wili... |
| Jul 11, 2014 | Hera Therapeutics raising $1.3M for antivirals work | Hera Therapeutics is housed in the Janssen Labs accelerator in San Diego. It was founded in late 2012 by Karl Hostetler, a professor emeritus at University of California, San Diego whose lab has focused on developing antivirals for a number... |
| May 14, 2014 | Janssen Labs expands its no-strings-attached incubator model to new San Francisco digs | I interviewed Richter last month, and she explained how the model was designed to move science forward, to improve the overall investment profile of the life science sector and to help Janssen’s pharmaceutical and biotech businesses grow th... |
| Jan 17, 2014 | 3 biotech investment trends gleaned from JP Morgan conference | Corporate venture capital funds investing in innovation: A PriceWaterhouse Cooper’s report on healthcare investment trends pointed out that biotech is in the top five for corporate venture capital investing. Edward Yu, a principal at PriceW... |
| Oct 21, 2013 | RNAi firm raises $5M to develop and deliver drugs that turn off disease-causing genes | Since its $1.3 million seed round closed early this summer, the company has licensed a portfolio of Marina Biotech’s unlocked nucleic acid technology. Two former employees of Nitto Denko, Joseph Payne and Pad Chivukula, started Arcturus ear... |
| Jun 3, 2013 | RNAi therapeutics startup sets up shop at Janssen labs, closes $1.3M seed round | “After we finalize licensing agreements and achieve in-vivo proof-of-concept with our IP, then we will be armed with the tools and data necessary to raise substantial money to take us forward to the clinic,” Payne said. The technique of RNA... |
| Main reason startups get rejected by venture capital: “Crappy teams” | The biggest reason startups get turned down by venture capital? They’ve got “crappy teams,” said Peter Thompson, a private equity partner at OrbiMed – one of the largest healthcare investment firms in the country. Thompson spoke with some c... |
Show more
Reviews 0
FAQ about Janssen
How much funding has Janssen raised?
Janssen has raised $1.3M in total across 1 funding round.
What has the press written about Janssen?
Parsers VC has collected 18 articles mentioning Janssen, among them “Main reason startups get rejected by venture capital: “Crappy teams”” (Nov 14, 2014) and “J&J launches Neuroscience Catalyst to seed academic spinouts” (Sep 17, 2014).
Is Janssen still active?
Janssen is probably closed: its latest activity on Parsers VC dates from Feb 14, 2015.